✨ Free AI Report
Nippon Shinyaku Co., Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Nippon Shinyaku Co., Ltd.
Company Research

Nippon Shinyaku Co., Ltd.: Business Overview, Financials & Competitive Analysis

Nippon Shinyaku is a Tokyo Stock Exchange-listed Japanese pharmaceutical and functional food company founded in 1911 and headquartered in Kyoto. The company manufactures and sells pharmaceuticals targeting urology, he...

Analyst-debate audio for Nippon Shinyaku Co., Ltd.

AskCyborg analysts argue the bull and bear cases for Nippon Shinyaku Co., Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Specialized Japanese pharma with rare disease focus and international expansion optionality offers stable cash generation and...

Read the full analyst-debate transcript →
Industry Pharmaceuticals & Functional Foods
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Nippon Shinyaku Co., Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Nippon Shinyaku Co., Ltd. Overview

Pro stress-test →

Nippon Shinyaku is a Tokyo Stock Exchange-listed Japanese pharmaceutical and functional food company founded in 1911 and headquartered in Kyoto. The company manufactures and sells pharmaceuticals targeting urology, hematology, rare diseases, and gynecology, alongside functional food ingredients and supplements, generating approximately ¥160 billion in annual revenue.

Strategic Profile

Pro stress-test →

Nippon Shinyaku maintains competitive advantage through specialized pharmaceutical portfolio in underserved therapeutic areas and strategic partnerships for rare disease treatments (ATSN-10 for Leber congenital amaurosis and RGX-121 for mucopolysaccharidosis in clinical trials). The company is expanding internationally with recent European rights acquisitions for Duchenne muscular dystrophy therapy, demonstrating a pivot toward high-growth rare disease and specialty pharmaceutical segments.

Competitive Landscape

Pro stress-test →

Nippon Shinyaku competes within specialized pharmaceutical niches rather than broadly against mega-cap pharma. Primary domestic competitors include Tsumura (herbal medicines) and regional Japanese pharma firms. International competition in rare diseases/specialty pharma includes Roche, Novartis, and Biogen, though Nippon Shinyaku's niche focus and partnerships provide differentiation in underserved therapeutic areas.

Industry Context

Nippon Shinyaku Co., Ltd. operates in Pharmaceuticals & Functional Foods.

Key facts

Founded: 1911 · Headquarters: Kyoto, Japan · Employees: 2,240 · Revenue: ¥160.2B · Market cap: ¥212.4B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Nippon Shinyaku Co., Ltd..

  • Revenue grew 8% YoY to ¥160.2B in 2024 with earnings up 26%, exceeding analyst estimates
  • Strategic partnerships in rare/intractable diseases (gene therapy, muscular dystrophy) position company in high-growth segments
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2025Binding agreement with Capricor Therapeutics for European distribution rights of Duchenne muscular dystrophy therapy (deramiocel)
  • 2024Full-year revenue ¥160.23B (+8.08% YoY), net income ¥32.56B (+25.94% YoY)
  • +1 moreTrack every material event for Nippon Shinyaku Co., Ltd. as it happens. Explore monitoring →
Get alerted when Nippon Shinyaku Co., Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Herbal and botanical medicinesJapan-based traditional medicine and functional food competitor→Rare disease and gene therapiesGlobal pharmaceutical leaders with extensive rare disease pipelines→Duchenne muscular dystrophy treatmentsPartner/competitor in rare muscular disease therapeutics→

Compare Nippon Shinyaku Co., Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Nippon Shinyaku Co., Ltd. operates in Pharmaceuticals & Functional Foods. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals & Functional Foods research →
NEW · MCP server

Ask your AI assistant about Nippon Shinyaku Co., Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Nippon Shinyaku Co., Ltd. and its top competitor on Cyborg Score”
“What did Nippon Shinyaku Co., Ltd. do this quarter?”
“Is Nippon Shinyaku Co., Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Nippon Shinyaku Co., Ltd. do?+
Nippon Shinyaku is a Tokyo Stock Exchange-listed Japanese pharmaceutical and functional food company founded in 1911 and headquartered in Kyoto. The company manufactures and sells pharmaceuticals targeting urology, he...
What is Nippon Shinyaku Co., Ltd.'s Cyborg Score?+
Nippon Shinyaku Co., Ltd. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Nippon Shinyaku Co., Ltd.'s main competitors?+
Named competitors include Herbal and botanical medicines, Rare disease and gene therapies, Duchenne muscular dystrophy treatments. The full competitive landscape is in the AskCyborg report.
How can I get the full Nippon Shinyaku Co., Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Nippon Shinyaku Co., Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Nippon Shinyaku Co., Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.